Method for treating rhinitis and sinusitis by rhamnolipids
The present invention is directed to methods for treating rhinitis or sinusitis in a subject. In one embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a formulation comprising an only active ingredient of an effective amount of rhamnolipid. In another embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a first active ingredient of an effective amount of a rhamnolipid and a second active ingredient of an effective amount of a corticosteroid, an antihistamine, a leukotriene antagonist, cromylin, an antibiotic, a sphingolipid, or a decongestant.
1. A method for treating rhinitis or sinusitis in a subject, comprising the steps of:
identifying a subject suffering from rhinitis or sinusitis, and
administering intranasally to the subject a first active ingredient of an effective amount of a rhamnolipid and a second active ingredient of an effective amount of a corticosteroid, an antihistamine, a leukotriene antagonist, a sphingolipid, or a decongestant, whereby symptoms of rhinitis or sinusitis in the subject are reduced.
2. The method according to claim 1 , wherein the first active ingredient and the second active ingredient are separately administered.
3. The method according to claim 1 , wherein the first active ingredient and the second active ingredient are combined in one formulation for administering.
4. The method according to claim 1 , wherein the second active ingredient is a corticosteroid selected from the group consisting of: budesonide, ciclesonide, flunisolide, fluticasone, mometasone, triamcinolone, dexamethasone, and a combination thereof.
5. The method according to claim 1 , wherein the second active ingredient is an antihistamine selected from the group consisting of: azelastine, olopatadine, loratadine, and a combination thereof.
6. The method according to claim 1 , wherein the second active ingredient is a decongestant and the decongestant is oxymetazoline.
7. The method according to claim 1 , wherein the second active ingredient is a sphingolipid.
8. The method according to claim 1 , wherein said rhamnolipid is selected from the group consisting of: rhamnolipid 1, rhamnolipid 2, and the combination thereof.
9. The method according to claim 1 , wherein said effective amount of the rhamnolipid is 0.005-10% (w/w).
10. The method according to claim 1 , wherein the method is for treating rhinitis.
11. The method according to claim 10 , wherein the rhinitis is allergic rhinitis, infectious rhinitis, non-allergic rhinitis, or mixed allergic and non-allergic rhinitis.
12. The method according to claim 1 , wherein the method is for treating sinusitis.
13. The method according to claim 9 , wherein said effective amount of the rhamnolipid is 0.1-5% (w/w).
14. The method according to claim 4 , wherein the effective amount of the corticosteroid is 0.01-0.06% (w/v).
15. The method according to claim 1 , wherein the second active ingredient is azelastine and its effective amount is 0.05-0.2% (w/v).
16. The method according to claim 1 , wherein the second active ingredient is olopatadine and its effective amount is 0.2-0.665% (w/v).
17. The method according to claim 1 , wherein the second active ingredient is oxymetazoline and its effective amount is 0.01-0.05% (w/v).
18. A method for treating rhinitis or sinusitis in a subject, comprising the steps of:
identifying a subject suffering from rhinitis or sinusitis, and
administering intranasally to the subject 0.005-10% (w/w) of a rhamnolipid and 0.02-0.06% (w/v) of ipratropium bromide, whereby symptoms of rhinitis or sinusitis in the subject are reduced.
19. A method for treating rhinitis or sinusitis in a subject, comprising the steps of:
identifying a subject suffering from rhinitis or sinusitis, and
administering intranasally to the subject 0.005-10% (w/w) of a rhamnolipid and 0.5-2.5% (w/v) of cromolyn, whereby symptoms of rhinitis or sinusitis in the subject are reduced.